Biomerica Inc. announced a multi-year exclusive distribution agreement with one of the UAE's most substantial healthcare conglomerates. This strategic alliance is set to revolutionize the accessibility and efficiency of colorectal cancer screening and breast examination technologies in the region. Biomerica has entered into a multi-year agreement with a UAE-based multi-billion dollar healthcare powerhouse, commencing with a large initial order for the Company?s at-home screening products, EZ Detect?

and Aware. The partnership will not only enhance the distribution of these innovative health screening tools across the UAE, but also work to engage various governmental health departments in integrating these tests into national health protocols. The collaboration between Biomerica and its UAE partner reflects a shared vision of reducing the burden of cancer through early detection and innovative healthcare solutions.

The companies are also exploring opportunities to introduce additional Biomerica products to the UAE, expanding their impact on healthcare improvement. EZ Detect? stands out as the most user-friendly at-home screening test for colorectal diseases currently available on the market.

It detects occult (hidden) blood in stool, which can be an early sign of colorectal cancer. FDA cleared and meticulously designed for convenience, EZ Detect? eliminates the need for cumbersome stool handling, offering a discreet and rapid screening experience directly in the comfort of the patient's home.

With a straightforward process?simply drop the test pad into the toilet, observe for a color change on the pad, then flush?the barrier to regular screening is significantly lowered, driving increased adoption rates and facilitating early detection efforts. This simplicity is critical in increasing screening adoption and early cancer detection rates. The recent approval of insurance reimbursement for EZ Detect?

by the Dubai Health Authority further underscores its public health importance and boosts its affordability and accessibility. Aware® is an innovative, FDA cleared device that increases tactile sensitivity during breast self-exams. By making it easier for women to detect changes in their breast tissue, Aware can play a crucial role in breast exams. Despite the lack of family history in over 70% of diagnosed cases, early detection through tools like Aware® significantly enhances the chances of successful treatment. Colorectal cancer is a prevalent and potentially life-threatening condition that affects millions of individuals worldwide.

According to the World Health Organization (WHO), in 2020 alone, more than 1.9 million new cases of colorectal cancer and more than 930,000 deaths due to colorectal cancer were estimated to have occurred worldwide. The organization estimates that colorectal cancer is the third most common cancer worldwide and is the second leading cause of cancer-related death worldwide. Colorectal cancer is the second most common cause of cancer death in the UAE.

In a study performed by Johns Hopkins University, EZ Detect? was preferred 10 to 1 by patients over another fecal occult blood test. Published studies have also indicated that the best colorectal screening test is ?the one that gets it done?.

Other colorectal screening tests require handling of the stool and sending the stool sample to a lab for processing, which can prove cumbersome. Because of the unpleasant difficulties of handling and mailing stool samples, a high percentage of these competing tests are never completed by patients. This potentially increases the risk for delayed detection of colorectal cancer.

Breast Cancer is the most common cancer among women. Unfortunately, every woman is potentially at risk, as approximately 70% of women diagnosed have no family history of breast cancer. Currently, there is no way to prevent breast cancer, so detecting the disease early is key to effective treatment.

Survival rates are as high as 99% when the cancer is found early and is still localized in the breast. However, if the cancer has spread to the regional lymph nodes, the 5-year survival rate is reduced to 86%. About 80% of breast cancers in young women are detected by women who themselves notice changes in their breasts, highlighting the important role that each woman can play in protecting their own health.